2022
Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021
Chehayeb R, Hood A, Wang X, Miksad R, Mougalian S, Lustberg M, Wang S, Greenup R, Pusztai L, Kunst N. Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021. JAMA Network Open 2022, 5: e2244204. PMID: 36445704, PMCID: PMC9709649, DOI: 10.1001/jamanetworkopen.2022.44204.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerErbB2-positive metastatic breast cancerHR-positive metastatic breast cancerLines of therapyMBC subtypesDrug costsBreast cancerMedical costsHuman epidermal growth factor receptor 2 receptor statusMBC treatmentERBB2-negative metastatic breast cancerAssociated direct medical costsEarly-stage breast cancerHormone receptorsFlatiron Health databaseMetastatic recurrence ratesDifferent drug regimensBreast cancer careData of patientsDirect medical costsNovel adjuvant therapySupportive care drugsOutcomes of interestCost-effectiveness analysisAdjuvant therapy
2017
Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer
Gamble C, Havrilesky L, Myers E, Chino J, Hollenbeck S, Plichta J, Kelly Marcom P, Shelley Hwang E, Kauff N, Greenup R. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer. Annals Of Surgical Oncology 2017, 24: 3116-3123. PMID: 28699130, PMCID: PMC5990891, DOI: 10.1245/s10434-017-5995-z.Peer-Reviewed Original ResearchConceptsRisk-reducing mastectomyOvarian cancer diagnosisIncremental cost-effectiveness ratioBRCA mutation carriersMonths of lifeMutation carriersMagnetic resonance imagingCancer diagnosisSurvival benefitOvarian cancerMutation statusMost BRCA1/2 mutation carriersThird-party payer perspectiveGreater survival benefitBreast cancer riskBRCA mutation statusBRCA1/2 mutation carriersBRCA2 mutation carriersBRCA2 mutation statusBRCA1 mutation carriersBreast cancer screeningMonte Carlo probabilistic sensitivity analysisCost-effectiveness ratioYears of lifeProbabilistic sensitivity analyses
2012
Application of ACOSOG Z0011 Criteria Reduces Perioperative Costs
Camp M, Greenup R, Taghian A, Coopey S, Specht M, Gadd M, Hughes K, Smith B. Application of ACOSOG Z0011 Criteria Reduces Perioperative Costs. Annals Of Surgical Oncology 2012, 20: 836-841. PMID: 23010735, DOI: 10.1245/s10434-012-2664-0.Peer-Reviewed Original ResearchMeSH KeywordsAxillaBreast NeoplasmsCombined Modality TherapyCost-Benefit AnalysisFemaleFollow-Up StudiesHumansLymph Node ExcisionLymphatic MetastasisMastectomy, SegmentalNeoplasm Recurrence, LocalNeoplasm StagingPractice Guidelines as TopicPrognosisRetrospective StudiesSentinel Lymph Node BiopsySurvival RateConceptsAxillary lymph node dissectionCompletion axillary lymph node dissectionPerioperative surgical managementOvernight admissionPerioperative costsZ0011 criteriaSurgical managementBreast cancerSentinel lymph node-positive breast cancerLymph node-positive breast cancerNode-positive breast cancerACOSOG Z0011 criteriaACOSOG Z0011 trialOvernight hospital admissionLymph node dissectionRetrospective chart reviewInvasive breast cancerBreast conservation therapyInpatient hospital daysPositive breast cancerExcellent regional controlPositive SLNZ0011 trialEligible patientsNode dissection